Respivert Limited

William Garth Rapeport

Peter Strong

Stuart Thomas Onions

Kazuhiro Ito

John King-Underwood

Peter John Murray

Catherine Elisabeth Charron

Jonathan Gareth Williams

David Michel Adrien Taddei

Simon Christopher Hirst

Kevin Joly

Ito Kazuhiro

Lindsey Cass

Catherine Elizabeth Charron

There is provided inter alia a compound of formula (I): wherein R, J, Ar, L, X, Rand Rare as defined in the specification, for use in the treatment of inflammatory disorders.

P38 MAP kinase inhibitors

The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

P38MAP kinase inhibitors

Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and/or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.

Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (RSV) infection

There are provided inter alia compounds of formula (I) wherein R, Ar, L, X, Rand Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.

P38MAP kinase inhibitor

The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

The present disclosure relates to compounds of formula (I): which are inhibitors of p38 mitogen-activated protein kinase enzymes, particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

p38 MAP kinase inhibitors

There is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, including all tautomers thereof, compositions comprising the same, use of said compound and compositions for treatment, in particular for the treatment of asthma and COPD, and processes for the preparation of said compound. 

Growing community of inventors

London, United Kingdom

William Garth Rapeport